235 related articles for article (PubMed ID: 27464858)
1. A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes.
Alshali KZ; Karawagh AM
Saudi Med J; 2016 Aug; 37(8):834-42. PubMed ID: 27464858
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Pinelli NR; Hurren KM
Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Drug Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors Based on Target Molecular Binding Occupancy.
Takayanagi R; Uchida T; Kimura K; Yamada Y
Biol Pharm Bull; 2018; 41(2):153-157. PubMed ID: 29386477
[TBL] [Abstract][Full Text] [Related]
4. Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%.
King AB; Montanya E; Pratley RE; Blonde L; Svendsen CB; Donsmark M; Sesti G
Endocr Pract; 2013; 19(1):64-72. PubMed ID: 23186975
[TBL] [Abstract][Full Text] [Related]
5. Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study.
García Díaz E; Guagnozzi D; Gutiérrez V; Mendoza C; Maza C; Larrañaga Y; Perdomo D; Godoy T; Taleb G
Endocrinol Nutr; 2016 May; 63(5):194-201. PubMed ID: 26976710
[TBL] [Abstract][Full Text] [Related]
6. GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.
Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; Serné EH; van Raalte DH
Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2125-32. PubMed ID: 27562916
[TBL] [Abstract][Full Text] [Related]
7. Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes.
Thompson AM; Trujillo JM
Ann Pharmacother; 2015 Mar; 49(3):351-9. PubMed ID: 25565404
[TBL] [Abstract][Full Text] [Related]
8. An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.
Madsbad S; Kielgast U; Asmar M; Deacon CF; Torekov SS; Holst JJ
Diabetes Obes Metab; 2011 May; 13(5):394-407. PubMed ID: 21208359
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.
Gadde KM; Vetter ML; Iqbal N; Hardy E; Öhman P;
Diabetes Obes Metab; 2017 Jul; 19(7):979-988. PubMed ID: 28205322
[TBL] [Abstract][Full Text] [Related]
11. [Twice-daily and weekly exenatide: clinical profile of two pioneer formulations in incretin therapy].
Lecube A; Bueno M; Suárez X
Med Clin (Barc); 2014 Sep; 143 Suppl 2():23-7. PubMed ID: 25437462
[TBL] [Abstract][Full Text] [Related]
12. Improved real-world glycaemic outcomes with liraglutide versus other incretin-based therapies in type 2 diabetes.
Lee WC; Dekoven M; Bouchard J; Massoudi M; Langer J
Diabetes Obes Metab; 2014 Sep; 16(9):819-26. PubMed ID: 24581276
[TBL] [Abstract][Full Text] [Related]
13. Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus.
Davies M; Speight J
Diabetes Obes Metab; 2012 Oct; 14(10):882-92. PubMed ID: 22420869
[TBL] [Abstract][Full Text] [Related]
14. Once-daily liraglutide (1.2 mg) compared with twice-daily exenatide (10 μg) in the treatment of type 2 diabetes patients: An indirect treatment comparison meta-analysis.
Twigg SM; Daja MM; O'leary BA; Adena MA
J Diabetes; 2016 Nov; 8(6):866-876. PubMed ID: 26729046
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials.
Xue X; Ren Z; Zhang A; Yang Q; Zhang W; Liu F
Int J Clin Pract; 2016 Aug; 70(8):649-56. PubMed ID: 27456750
[TBL] [Abstract][Full Text] [Related]
16. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
[TBL] [Abstract][Full Text] [Related]
17. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Mikhail N
Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus.
Owens DR; Monnier L; Bolli GB
Diabetes Metab; 2013 Dec; 39(6):485-96. PubMed ID: 24156868
[TBL] [Abstract][Full Text] [Related]
19. Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
Garber AJ
Am J Manag Care; 2010 Aug; 16(7 Suppl):S187-94. PubMed ID: 20809667
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
